Organ Dysfunction in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors

BACKGROUND: Real‐world data enables evaluation of immune checkpoint inhibitor (ICI) use in advanced melanoma management. We examined characteristics and outcomes of ICI‐treated patients with advanced melanoma and organ dysfunction (baseline and emergent). MATERIALS AND METHODS: This retrospective ob...

Descripción completa

Detalles Bibliográficos
Autores principales: Spillane, Susan, Baxi, Shrujal, Torres, Aracelis Z., Lenis, David, Freedman, Andrew N., Mariotto, Angela B., Sharon, Elad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Melanoma and Cutaneous Malignancies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648349/
https://www.ncbi.nlm.nih.gov/pubmed/33094874
http://dx.doi.org/10.1634/theoncologist.2020-0055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648349/
https://www.ncbi.nlm.nih.gov/pubmed/33094874
http://dx.doi.org/10.1634/theoncologist.2020-0055

Ejemplares similares